saying, discuss special our the extend and Thanks for to morning, us. to and hear call maybe analysts financial on who on Rachel. any our a And let Thank investors everyone. that we by focus start cancer to fall immuno-oncology cancer. platform ATLAS today an has welcome to developing update programs. progress decision how applying want joining Good made me with the you results immuno-oncology, new broadly advancing are identification and on our team generation pleased next exclusively I to antigen vaccines since our to last Genocea
recently strategy. new We know investors was we Capital. strategy. exciting $XX differentiator. led the you like The including As top investors, of to a our this platform, we endorsement to ability team Lifescience’s completed support our is This Genocea technology and believe attract key new strong financing financing these our a and by especially NEA million Vivo which believe is ATLAS
XXXX to this our expect enable GEN-XXX, larger to enrolling of first in our the cancer the We and candidate first from raise half vaccine clinical Phase begun lead have of portion neo-antigen our report program. will us data X/Xa
So, to to and picture, big like the for reasons few the ATLAS on is why our now time platform? are looking I’d today. cancer vaccines be a highlight at There focusing immuno-oncology, right us
in our of the acceleration of all and can breaks checkpoint past how to We cancer there kill understanding T in blockade cells. the remove cell advances significant from immune cancer. has the been T the years the how Over understanding a fight arm system to several cells know the
combination the specifically antigen themselves. using cell response, but in of checkpoint do the checkpoints immuno-oncology neoantigen are effective efforts. individual's this existing proportion the to enough marginally amplify cells help vaccines, and at cancer of such their to at neoantigen predicting drive neoantigen’s believe by predictive to much XX% outcome on This focus promise improving and role responses checkpoint inhibitors. patients drive of early cancer. that vaccines which there to effective will effective the in in-silico neoantigens will an vaccines, understand about ineffective than potentially in-silico work critical larger early such better cancer, with has that direct of important. best in play One an the of ATLAS using is Early at work cancer which XX% shows mostly neoantigen are our tools cells room patient in the XX% targets built select and ineffective the for a also are vaccine have curing these predicting cargo, XX% neoantigen in-silico to suggests opportunity is is can vaccines using a We lead methods to cancer envision shows which to identification benefits. that personal also shown hopefully transformative cancer of work specifically Remember neoantigens promise and patients the CDX But on but and completely vaccines neoantigen's We efficacy vaccines. in validate way to cells, critically for concept the wasted toward because significantly these to killing to T of promise vaccines, neoantigens and the tools improvement. is the the best, can potential at approach T for in opportunity provide predicted of in neoantigen curative of CDX these just T a inhibitors best not patient neoantigen carry effective We
of for We’re predicted woefully flu importance because other is all incorrectly words, largely of antigens. wrong we year's year's vaccine vaccine. antigens ineffective living a right ineffective, recent In This antigens the this vaccine the example vaccine.
targets Genocea, say matter. we As here at
reinforced SITC the about ATLAS the Our we point The targets my November reinforced limitations methods. last that in-silico of data at presented data presented this matter. Meeting notion
such ongoing neoantigens fact be methods strongly many ineffective. the identified and those pursued in-silico true of could could suggested that data targets using therefore Our studies in not be and being clinical
predict each how to their that neoantigens; in own and ATLAS not discussed identify recall, actual ATLAS specific previously, is, T type problem? range and HLA patient’s this cancer uniquely CDX words, Moreover we've And and/or Cells of uniquely to the person's burden. that those is guides a also ATLAS whether comprehensively exclude would be those only appear in good previously makeup compelling cells In pre-existing vaccine. antigens clinically to existing solve is responses. with cancers, shows good and particularly that know exhibit Neoantigens this presenting it neoantigens ATLAS be which antigen pre-existing broad development responses, therapeutic other Cell neoantigens. does true to a immune So which has ATLAS to but uses neoantigens boost and response. how high As those can from associated patient's stimulatory, immune including independent or CDX infectious genetic patient mutational of disease they pre-existing with important T low or response does easier or across bad. for include And pre-existing effective be been to inhibitory, response we and think profile each as immunity of cancer. it should pre-existing personalized not in bad vaccination us
with ATLAS to believe cancer we effective the have more vaccines. again, develop opportunity we So
an Our vaccine to IND GEN-XXX GEN-XXX designed expect power very using identify vaccine to peptide-based uses be first an is vaccine cancer each neoantigens is ATLAS soon. the for patient. file we of for adjuvanted to that which ATLAS
range into the combine lung synthetic license formulate drug clinical into for has component synthetic peptides believe drug driving file used record for with master of shown induce will manufacture paired to personalized Hiltonol manufactured We peptides important our an and existing When of Oncovir called adjuvant we when then Hiltonol of course product antigens. cell a with neoantigens, has in GEN-XXX be agreement entered Hiltonol or will cancers. combination for vaccine ability those and GMP and across with create GEN-XXX. extensive alone poly-ICLC. cancer We T to efficacy and recently lung each supply the adjuvant a is vaccines responses, with an and of which has tolerability of
In expect make for to successful high melanoma, in IND patient monitor for cell disease the A enroll enroll six Assuming post personalized neck risk will X/Xa of we this the vaccine including have patients relapse. cancer, variety safety middle a start will have These of types a each dosing. trial we and been acceptance, around patients the and of lung filing head and GEN-XXX cancers. tumour FDA and non-small Phase and and year patients a of europhilo of in immunogenicity cleared and will a neoantigen part but trial, we
looking data in we to selection and potential larger to superiority pipeline, looking call at GEN-XXX these of B technologies are vaccine disease. A this expect Part checkpoint efforts, the based middle the from of expand pair of delivery the to trial XXXX. we of the inhibitors and are peers ATLAS Next-Generation humans in-silico and the versus severe XX. patients optimal with trial, important when parts XXXX We around antigens in our the half The first to C first with in cancer will will data we as of they antigen also start immunogenicity be ATLAS's that demonstrate create prospectively with in first be tools. in a cancer Gen expecting These to Alongside combination identified our efficacy more we represent opportunity researching
of value In through to the to cancer of vaccines. maximize addition, ATLAS partnerships the seek exploration we continue in
the as For TAAs to associated antigens. presented virus or of well support example, use associated data tumor ATLAS as or antigens we to identify
already identified clinical have We potential interest. TAAs of
SITC research. at posters this two presented we fact, In that highlight
vaccine, the in also patients the diagnosis common for identified potential colorectal while in a antigen The blood-based And cancer. development first colorectal showing the for showing in cancer of non-invasive supporting early AAs with potential TAAs identified assay patients immunotherapy. a use in lung inclusion novelty of potential detection and for cancer second,
to We collaboration are opportunities. seeking advance these
already we Genocea meet the are is virus. T studied that, Virus of I having Cell also of evolve up financials turn discuss or of in development an momentum to over before creating call Epstein-Barr unexpected caused prospect With cancer to the to Jonathan? why Jonathan continue to by extensively With behind this against responses where strategy, looking needs. to this program the ATLAS it data antigens future We EBV vaccines virus, open don't differentiated cancer gathering identified EBV partner we presented questions. our to
